La prescription médicale des radiopharmaceutiques au sein d’un service de médecine nucléaire

Biechlin-Chassel, M.-L.; Lao, S.; Bolot, C.; François-Joubert, A.

doi:10.1016/j.mednuc.2010.06.013

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, as they are medication, they must be prescribed by a nuclear medicine physician and managed by a radiopharmacist, who must ensure the dispensing process, including pharmaceutical analysis of the prescription. 1 Radiopharmaceuticals can be used for diagnostic or therapeutic procedures. The effects of low-dose radiation exposure, which are encountered during diagnostic procedures in nuclear medicine, are poorly understood although several studies have suggested an overestimation of the risk.…”

Section: Introductionmentioning

confidence: 99%

How can we optimise the pharmaceutical analysis of radiopharmaceutical pediatric prescriptions?

et al. 2021

View full text Add to dashboard Cite

Objectives In France, dispensation is defined by the validation of a prescription associated with a pharmaceutical analysis, preparation of medication and provision of information necessary for proper use. There are very few data available in the literature that describe prescription analysis modality in radiopharmacy. The aim was to secure a place for paediatric prescription analysis in radiopharmacy by designing a flow chart validated by experts. Methods Experts from different disciplines and health setups (ie, public, private) were selected to represent the various paediatric patient care processes. A review of the literature on pharmaceutical analysis and paediatric prescription in radiopharmacy was conducted. A Delphi approach comprising two rounds (Google Form survey) was used to validate the flow chart. Answers were graded according to a nine-point Likert scale for agreement. Open-ended questions allowed experts to comment on the propositions. A consensus between experts was reached if more than 70% of the experts agreed on an item and fewer than 30% disagreed. Results Sixty-five experts were solicited: two oncopaediatricians, three nuclear medicine physicians, 46 radiopharmacists, three residents in radiopharmacy, one hospital pharmacist, five medical physicists, one pharmacy technician, two X-ray technicians and two patients who are pharmacists. The first round survey included a draft of the flow chart: 31 experts answered (48%). All professional disciplines were represented except pharmacy technician. The second round survey was sent with a new flow chart that had been improved by the experts' comments. After 3 weeks, 18 answers were obtained (28%). After the first round, consensus was obtained for each item. Experts gave a total of 97 comments. The second flow chart had three steps: regulatory aspects, patient data, and radiopharmaceutical data, and it was accompanied by descriptive text explaining the field of application. Conclusion The resulting flow chart will secure the pharmaceutical analysis step for this special patient population.

show abstract

Section: Introductionmentioning

confidence: 99%